Eidos Therapeutics, Inc. Common Stock
EIDX
EIDX was delisted on the 25th of January, 2021.
121 hedge funds and large institutions have $1.48B invested in Eidos Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 24 increasing their positions, 38 reducing their positions, and 16 closing their positions.
188% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 16
140% more capital invested
Capital invested by funds: $616M → $1.48B (+$863M)
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
33% more funds holding
Funds holding: 91 → 121 (+30)
37% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 38
47% less call options, than puts
Call options by funds: $5.02M | Put options by funds: $9.49M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$53M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$26.3M |
| 3 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$24.3M |
| 4 |
DAM
DLD Asset Management
New York
|
+$21.2M |
| 5 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$109M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$50.2M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$21.8M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$12.9M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$10.4M |
EIDX Hedge Fund Activity: Q4 2020 in Review
121 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q4 2020, worth a combined $1.48B — up 140% from $616M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new EIDX positions and 16 closed out — a net gain of 30 holders — while 24 added to existing stakes and 38 trimmed.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $53M. The largest seller was RA Capital Management, exiting entirely with an estimated $109M sold.
- 121 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q4 2020, up from 91 in Q3 2020.
- Funds reported $1.48B of Eidos Therapeutics, Inc. Common Stock stock for Q4 2020, up 140% quarter-over-quarter.
- 46 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q4 2020 and 16 closed out, a net change of +30 holders.
- The largest Eidos Therapeutics, Inc. Common Stock buyer in Q4 2020 was Magnetar Financial, an estimated $53M added.
- The largest Eidos Therapeutics, Inc. Common Stock seller in Q4 2020 was RA Capital Management, an estimated $109M sold.
Based on aggregated 13F filings for Q4 2020.